Daclizumab in multiple sclerosis: a high-yield extension study

Lancet Neurol. 2014 May;13(5):443-4. doi: 10.1016/S1474-4422(14)70056-0. Epub 2014 Mar 19.

Authors

Frederik Barkhof¹, Olga Ciccarelli²

Affiliations

¹ Department of Radiology and Nuclear Medicine, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, Netherlands. Electronic address: f.barkhof@vumc.nl.
² Queen Square Centre, University College London Institute of Neurology, University College London, London, UK; National Institute for Health Research Biomedical Research Centre, University College London Hospitals, London, UK.

PMID: 24656610
DOI: 10.1016/S1474-4422(14)70056-0

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Daclizumab
Female
Humans
Immunoglobulin G / therapeutic use*
Immunosuppressive Agents / therapeutic use*
Male
Multiple Sclerosis, Relapsing-Remitting / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
Immunoglobulin G
Immunosuppressive Agents
Daclizumab